Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, reports prolonged survival in a 12-year-old Great Dane presenting with primary bronchoalveolar adenocarcinoma. The animal had a life expectancy no greater than 30 days but survived over 50 weeks post-diagnosis after being given the proprietary chaperone-rich-cell-lysate (CRCL) vaccine developed by Dr. Michael Har-Noy.
Prior to treatment with the CRCL vaccine, the Great Dane displayed symptoms of nystagmus, ataxia, and hind-end collapse. Dr. Michael Har-Noy said that a chest X-ray demonstrated a tumor in the right lung's cranial lobe. Broncholalveolar adenocarcinoma was subsequently diagnosed via ultrasound-guided fine needle biopsy, and thoracotomy and lobectomy was then performed on the animal. Dr. Michael Har-Noy noted that pathologic analysis of the tumor showed a grade III bronchoalveolar carcinoma with vascular infiltration and lymph node metastasis, with an average survival of 6 – 27 days.
Using his proprietary technology, Dr. Michael Har-Noy incorporated a 10 gram tumor specimen into a CRCL vaccine and then administered it every week to the Great Dane. Also, Dr. Michael Har-Noy treated the dog with 12 applications of topical Imiquimod, a Toll-like receptor 7 (TLR7) agonist, in order to stimulate local Langerhans cells. Additionally, at 30 weeks, a bacillus Calmette-Guerin (BCG) shot was given at 30 weeks to further stimulate the canine immune response.
Dr. Michael Har-Noy says the Great Dane remained in relatively good condition until it had a relapse 44 weeks after the first CRCL vaccine treatment. The dog went on to suffer severe gastrointestinal bleeding and had to be euthanized just after 50 weeks post diagnosis.
Dr. Michael Har-Noy notes this is the first report of significantly prolonged survival in a canine with a biopsy-proven diagnosis of grade III/stage III bronchoalveolar adenocarcinoma. This case suggests that Dr. Michael Har-Noy's CRCL vaccine combined with topical Imiquimod is a very safe and effective therapy for canine malignancy.
Dr. Michael Har-Noy is testing his CRCL vaccine in patients with a wide variety of metastatic tumors that are refractory to conventional therapy. Please visit www.immunocare.net for more information.